CAPN9 Antibody

What is CAPN9 and what cellular functions does it regulate?

CAPN9 (Calpain 9) is a member of the calpain family of calcium-dependent proteases, also known as NCL4, belonging to the peptidase C2 family. It plays critical roles in multiple cellular processes including cell signaling pathways, apoptosis regulation, cell cycle progression, and cytoskeletal remodeling. CAPN9 is particularly notable for its tissue-specific expression pattern, with pronounced expression in the gastrointestinal tract. Research has shown that CAPN9 can be down-regulated in gastric cancer tissues and in gastric cell lines, suggesting potential tumor suppressor functions in certain contexts . The protein is involved in proteolytic regulation of signaling pathways, and recent research has implicated it in TGFβ-induced myofibroblast differentiation, indicating its potential role in fibrotic disease processes .

What types of CAPN9 antibodies are available for research applications?

Several validated CAPN9 antibodies are available for research applications, with polyclonal antibodies being the most commonly used. Notable examples include:

• Rabbit polyclonal antibodies (such as 17556-1-AP) that target specific epitopes of the CAPN9 protein

• CAPN9 Rabbit Polyclonal Antibody (CAB17085) developed against recombinant fusion proteins containing amino acids 391-690 of human CAPN9

These antibodies have been validated for multiple applications including Western Blotting (WB), Immunohistochemistry (IHC), and Immunofluorescence (IF)/Immunocytochemistry (ICC) . Typically, these are unconjugated antibodies stored in PBS buffer with sodium azide and glycerol, requiring appropriate dilution for specific applications .

What are the optimal dilution ratios for different CAPN9 antibody applications?

Based on validated protocols, the following dilution ratios are recommended for optimal results with CAPN9 antibodies:

It is strongly recommended that researchers titrate the antibody in each specific testing system to obtain optimal results, as sample types and experimental conditions can significantly impact antibody performance . For antigen retrieval in IHC applications, TE buffer at pH 9.0 is suggested, though citrate buffer at pH 6.0 may also be used as an alternative .

What cell and tissue types have been validated for CAPN9 antibody reactivity?

CAPN9 antibodies have demonstrated positive reactivity in multiple cell and tissue types across different applications:

• Western Blot (WB): Successfully detected in human stomach tissue, HL-60 cells, and mouse small intestine tissue

• Immunohistochemistry (IHC): Validated in human stomach cancer tissue, kidney tissue, lung tissue, ovary tissue, normal stomach tissue, and testis tissue

• Immunofluorescence (IF)/ICC: Confirmed reactivity in HepG2 cells

The antibodies typically show cross-reactivity across human, mouse, and rat samples, making them valuable tools for comparative studies across species . This wide range of validated tissues makes CAPN9 antibodies particularly useful for researchers investigating gastrointestinal physiology and pathology.

How should antigen retrieval be performed for optimal CAPN9 detection in FFPE tissue sections?

For optimal detection of CAPN9 in formalin-fixed paraffin-embedded (FFPE) tissue sections, heat-induced epitope retrieval (HIER) is strongly recommended. The preferred method uses TE buffer at pH 9.0, which has been validated to provide optimal staining intensity and specificity in multiple tissue types . The protocol should include:

• Deparaffinization and rehydration of tissue sections

• Immersion in TE buffer (pH 9.0)

• Heat treatment (typically 95-98°C for 15-20 minutes)

• Gradual cooling to room temperature

• Washing steps before proceeding with antibody incubation

As an alternative approach, citrate buffer at pH 6.0 may also be used for antigen retrieval, though this may yield variable results depending on tissue type and fixation conditions . It is advisable to include positive control tissues (such as stomach tissue) to validate the effectiveness of the antigen retrieval procedure in each experimental run.

How can researchers validate the specificity of CAPN9 antibody staining?

Validating CAPN9 antibody specificity requires a multi-faceted approach:

• Positive controls: Include known CAPN9-expressing tissues (such as stomach tissue) or cell lines (such as HL-60 or HepG2)

• Western blot analysis: Confirm a single band or expected pattern at the observed molecular weight range of 60-66 kDa

• Enhanced validation methods:

  • siRNA knockdown: Evaluate decrease in antibody staining upon CAPN9 downregulation

  • Independent antibodies: Compare staining patterns using antibodies targeting different epitopes of CAPN9

  • Orthogonal validation: Correlate protein expression with RNA expression data from platforms like the Human Protein Atlas

• Negative controls:

  • Omission of primary antibody

  • Use of isotype control

  • Testing in tissues known to lack CAPN9 expression

What are common sources of false positive or false negative results when using CAPN9 antibodies?

Several factors can contribute to false results when working with CAPN9 antibodies:

Sources of False Positives:

• Cross-reactivity with other calpain family members (due to sequence homology)

• Excessive antibody concentration leading to non-specific binding

• Insufficient blocking or washing steps in protocols

• Inappropriate antigen retrieval methods causing epitope alteration

• Endogenous peroxidase or alkaline phosphatase activity (if using enzyme-based detection systems)

Sources of False Negatives:

• Insufficient antigen retrieval, particularly in FFPE tissues

• Protein degradation during sample preparation

• Epitope masking due to protein-protein interactions or post-translational modifications

• Using suboptimal antibody dilutions

• Ineffective detection systems or substrate incubation times

To mitigate these issues, researchers should always include appropriate controls, optimize protocols for each experimental system, and consider using multiple detection methods or antibodies targeting different epitopes when critical results are being evaluated .

How should researchers account for variations in CAPN9 molecular weight observed in Western blot analysis?

When performing Western blot analysis of CAPN9, researchers may observe variations in the detected molecular weight (typically 60-66 kDa) compared to the calculated molecular weight of 72 kDa . To properly account for these variations:

• Reference the observed rather than calculated weight: Use the empirically observed range (60-66 kDa) as the primary reference point rather than the theoretical value

• Consider post-translational modifications: Proteolytic processing, phosphorylation, glycosylation, or other modifications may alter the migration pattern of CAPN9

• Evaluate sample preparation effects: Different lysis buffers, reducing agents, or heating conditions may affect protein conformation and electrophoretic mobility

• Use positive controls: Include validated CAPN9-expressing samples (such as stomach tissue lysate) as reference standards on each blot

• Employ gradient gels: When first characterizing CAPN9 in a new system, consider using gradient gels to better resolve potential isoforms or modified versions of the protein

• Validate with multiple antibodies: If available, confirm findings using antibodies targeting different epitopes of CAPN9

These approaches help ensure accurate identification of CAPN9 and prevent misinterpretation of Western blot results, especially when studying novel tissue types or experimental conditions .

How can CAPN9 antibodies be used to investigate its role in fibrotic disease processes?

Recent research has implicated CAPN9 in TGFβ-induced myofibroblast differentiation and fibrotic disease processes . Researchers can leverage CAPN9 antibodies to investigate these connections through several approaches:

• Tissue expression profiling: Use IHC to compare CAPN9 expression between normal and fibrotic tissues across multiple organs including lung, liver, and kidney

• Co-localization studies: Employ double immunofluorescence to assess the spatial relationship between CAPN9 and known fibrosis markers (α-SMA, collagen I, fibronectin)

• TGFβ stimulation experiments: Monitor CAPN9 expression changes in response to TGFβ treatment in relevant cell types using Western blot and immunofluorescence

• Intervention studies: Evaluate the effects of CAPN9 knockdown or inhibition on myofibroblast activation markers and extracellular matrix production

• Animal model analysis: Capitalize on findings from Capn9 knockout mice studies that demonstrated protection against bleomycin-induced lung fibrosis, carbon tetrachloride-induced liver fibrosis, and angiotensin-related fibrotic processes

These approaches can help elucidate the mechanistic role of CAPN9 in fibrosis progression and potentially identify new therapeutic targets for fibrotic diseases across multiple organ systems.

What are the best approaches for studying CAPN9 in gastric cancer using available antibodies?

Given CAPN9's reported downregulation in gastric cancer tissues , researchers can employ these strategies using available antibodies:

• Comparative expression analysis: Use IHC to evaluate CAPN9 expression patterns in:

  • Normal gastric mucosa

  • Precancerous lesions

  • Different histological subtypes and stages of gastric cancer

• Prognostic significance assessment: Correlate CAPN9 expression levels with:

  • Clinical outcomes

  • Tumor invasion depth

  • Lymph node metastasis

  • Response to therapy

• Mechanistic studies in cell lines:

  • Compare CAPN9 expression across gastric cancer cell lines using Western blot

  • Perform gain-of-function and loss-of-function experiments to assess CAPN9's impact on proliferation, invasion, and apoptosis

  • Evaluate CAPN9's relationship with known gastric cancer signaling pathways

• Proteomic analyses:

  • Use CAPN9 antibodies for immunoprecipitation to identify interaction partners

  • Combine with mass spectrometry to characterize CAPN9 substrates in gastric tissues

• Patient-derived xenograft (PDX) models:

  • Validate CAPN9 expression patterns in PDX models

  • Test therapeutic approaches targeting CAPN9-associated pathways

These multi-dimensional approaches can provide comprehensive insights into CAPN9's potential role as a biomarker or therapeutic target in gastric cancer .

How can researchers integrate CAPN9 antibody-based assays with genetic approaches to understand its function?

Integrating antibody-based assays with genetic approaches provides powerful insights into CAPN9 function:

• Correlation of protein and mRNA expression:

  • Compare CAPN9 protein levels (detected by antibodies) with mRNA expression from RNA-seq or qPCR

  • Identify potential post-transcriptional regulatory mechanisms when discrepancies are observed

• CRISPR/Cas9 gene editing coupled with antibody validation:

  • Generate CAPN9 knockout or knockin cell lines

  • Use antibodies to confirm successful genetic modification

  • Analyze downstream effects on potential substrate proteins

• Rescue experiments:

  • Reintroduce wild-type or mutant CAPN9 into knockout models

  • Use antibodies to verify expression levels and localization patterns

  • Assess functional restoration through phenotypic assays

• Animal model studies:

  • Leverage findings from Capn9 knockout mice studies that showed protection from various fibrosis models

  • Use antibodies to characterize protein expression in tissue-specific conditional knockout models

  • Correlate phenotypic observations with protein expression patterns

• Single-cell analysis:

  • Combine antibody-based flow cytometry or imaging with single-cell RNA-seq

  • Identify cell populations with varied CAPN9 expression and correlate with functional states

This integrated approach allows researchers to validate antibody specificity while gaining deeper insights into CAPN9's functional roles across different biological contexts and disease states.

What potential exists for developing CAPN9 as a therapeutic target based on current antibody research?

Current research using CAPN9 antibodies has revealed promising therapeutic potential:

• Fibrosis intervention: Studies with Capn9 knockout mice have demonstrated protection from multiple fibrosis models, including bleomycin-induced lung fibrosis, carbon tetrachloride-induced liver fibrosis, and angiotensin-related fibrotic processes . This suggests CAPN9 inhibition could be a viable therapeutic strategy for fibrotic diseases.

• Cancer applications: Given CAPN9's differential expression in gastric cancer , antibody-based research could help determine if:

  • CAPN9 restoration strategies might have anti-tumor effects

  • CAPN9 expression levels could serve as predictive biomarkers for treatment response

  • CAPN9-dependent pathways represent novel therapeutic targets

• Development of specific inhibitors: Antibody-based structural and functional studies can guide the rational design of small molecule inhibitors specific to CAPN9, avoiding the off-target effects associated with pan-calpain inhibitors.

• Antibody-drug conjugates: The tissue-specific expression pattern of CAPN9 could potentially be exploited for targeted drug delivery through antibody-drug conjugates.

• Biomarker development: Validation of CAPN9 antibodies for diagnostic applications could lead to the development of prognostic or predictive biomarkers for gastrointestinal diseases.

These therapeutic directions rely heavily on continued refinement and validation of CAPN9 antibodies to understand the protein's exact role in disease processes.

How can multiple antibodies targeting different CAPN9 epitopes be used for comprehensive analysis?

Employing multiple antibodies targeting distinct CAPN9 epitopes offers several advantages for rigorous research:

• Enhanced validation: Concordant results from independent antibodies provide stronger evidence for specific CAPN9 detection, as recommended by the Human Protein Atlas validation protocols .

• Domain-specific analysis:

  • Antibodies targeting different functional domains (catalytic, calcium-binding, etc.)

  • Detection of potential processing events or isoforms

  • Identification of domain-specific protein interactions

• Improved sensitivity across applications:

  • Some epitopes may be more accessible in certain applications (WB vs. IHC)

  • Combined use can increase detection sensitivity

  • Overcoming epitope masking issues in specific tissue contexts

• Multiplexed imaging:

  • Using differently labeled antibodies against distinct CAPN9 epitopes

  • Simultaneously visualizing multiple conformational states

  • Co-localization with substrate proteins or interaction partners

• Functional blocking studies:

  • Using antibodies that target functional domains to inhibit enzymatic activity

  • Comparing effects of blocking different domains to understand structure-function relationships

This multi-epitope approach not only enhances detection reliability but also provides deeper insights into CAPN9's structural dynamics and functional states across experimental conditions.

What novel techniques are being developed to study CAPN9 protein-protein interactions using antibodies?

Several cutting-edge techniques are being applied to study CAPN9 interactions:

• Proximity Ligation Assay (PLA):

  • Allows visualization of protein interactions in situ with single-molecule sensitivity

  • Combines antibody recognition with DNA amplification technology

  • Enables detection of transient or weak CAPN9 interactions with potential substrates

• Bio-ID or APEX proximity labeling:

  • Fusion of CAPN9 with promiscuous biotin ligases

  • Antibody-based detection of biotinylated proximity partners

  • Identification of the CAPN9 interactome in living cells

• Förster Resonance Energy Transfer (FRET):

  • Fluorescently-labeled antibodies or antibody fragments

  • Real-time monitoring of CAPN9 interactions

  • Analysis of calcium-dependent conformational changes

• Co-immunoprecipitation coupled with mass spectrometry:

  • CAPN9 antibodies used for immunoprecipitation from tissue lysates

  • Mass spectrometry identification of co-precipitated proteins

  • Validation of interactions through reciprocal co-IP experiments

• Spatial proteomics:

  • Combining antibody-based imaging with mass spectrometry

  • Mapping CAPN9 interactions in their subcellular context

  • Correlation with functional outcomes in specific cellular compartments

These advanced techniques are expanding our understanding of CAPN9's functional networks and may reveal novel roles in cellular signaling pathways relevant to both normal physiology and disease states.